Key Takeaways Sustained demand for key therapies and new product approvals support revenue growth, expanded margins, and enhanced operating leverage in both established and emerging markets. Streamlined cost structure, controlled spending, and a robust cash position reduce financial risk while enabling reinvestment in pipeline assets and supporting future earnings growth.Read more
Key Takeaways YUPELRI and ampreloxetine are positioned for market leadership and profit growth, with potential to outperform current expectations in both COPD and rare disease segments. Strong financial discipline and underappreciated global opportunities enhance Theravance's ability to accelerate shareholder returns and capitalize on emerging high-margin revenue streams.Read more
Key Takeaways Heavy reliance on a limited product lineup raises vulnerability to pricing pressures, generic competition, and uncertain future revenue streams. Heightened regulatory, payer, and industry challenges may dampen profitability and hinder the successful commercial launch of new drug candidates.Read more
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
